Cargando…

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial

IMPORTANCE: The prevention of chemotherapy-induced nausea and vomiting has an important role in the overall management of cancer treatment. OBJECTIVE: To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, De-Shen, Hu, Ming-Tao, Wang, Zhi-Qiang, Ren, Chao, Qiu, Miao-Zhen, Luo, Hui-Yan, Jin, Ying, Fong, William Pat, Wang, Shu-bin, Peng, Jie-wen, Zou, Qing-feng, Tan, Qiong, Wang, Feng-Hua, Li, Yu-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035650/ https://www.ncbi.nlm.nih.gov/pubmed/33835174 http://dx.doi.org/10.1001/jamanetworkopen.2021.5250

Ejemplares similares

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
por: Liu, Yingchao, et al.
Publicado: (2023)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis
por: Zhang, Min, et al.
Publicado: (2023)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
por: Emami, Hamid, et al.
Publicado: (2015)

A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting
por: Liu, Guang, et al.
Publicado: (2022)

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
por: Humphreys, Samantha, et al.
Publicado: (2013)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
por: Giagnuolo, Giovanna, et al.
Publicado: (2019)

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting
por: Nijstad, A. Laura, et al.
Publicado: (2022)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015)

5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
por: Hayashi, Toshinobu, et al.
Publicado: (2020)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
por: Yoo, Jae Hwa, et al.
Publicado: (2018)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients
por: Takahashi, Toshiaki, et al.
Publicado: (2010)

Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study
por: MATSUDA, Masahide, et al.
Publicado: (2016)

Evidence Summary for Nonpharmacological Management of Chemotherapy-Induced Nausea and Vomiting
por: Li, Kexuan, et al.
Publicado: (2022)

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone
por: Lee, Se-Jin, et al.
Publicado: (2012)

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
por: Wang, Xiao-fei, et al.
Publicado: (2014)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting
por: Wang, Nan, et al.
Publicado: (2020)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial
por: Thanuja, Ingilala L, et al.
Publicado: (2021)

Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
por: Fang, Bao-Xia, et al.
Publicado: (2017)

Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial
por: Moon, Hyoung Yong, et al.
Publicado: (2014)

Aprepitant in a Multimodal Approach for Prevention of Postoperative Nausea and Vomiting in High-Risk Patients: Is There Such a Thing as “Too Many Modalities”?
por: Hache, John J., et al.
Publicado: (2009)

Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial
por: Grigio, Thiago Ramos, et al.
Publicado: (2020)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_veaoma2aohlbf80a6fapmflraf